title: Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.
abstract: Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost-effectiveness involved with the use of the drug.
authors.affiliation: Medical Oncology Unit, National Cancer Institute "Giovanni Paolo II", Bari, Italy.
authors.forename: Nicola
authors.initials: N
authors.lastname: Silvestris
authors.forename: Bruno
authors.initials: B
authors.lastname: Vincenzi
authors.forename: Anna Elisabetta
authors.initials: AE
authors.lastname: Brunetti
authors.forename: Fotious
authors.initials: F
authors.lastname: Loupakis
authors.forename: Emanuela
authors.initials: E
authors.lastname: Dell'Aquila
authors.forename: Antonio
authors.initials: A
authors.lastname: Russo
authors.forename: Mario
authors.initials: M
authors.lastname: Scartozzi
authors.forename: Riccardo
authors.initials: R
authors.lastname: Giampieri
authors.forename: Stefano
authors.initials: S
authors.lastname: Cascinu
authors.forename: Vito
authors.initials: V
authors.lastname: Lorusso
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tonini
authors.forename: Alfredo
authors.initials: A
authors.lastname: Falcone
authors.forename: Daniele
authors.initials: D
authors.lastname: Santini
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000502:physiology; D006801:Humans; D009154:Mutation; D009362:Neoplasm Metastasis; D051059:PTEN Phosphohydrolase / Q000502:physiology; D010597:Pharmacogenetics; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000502:physiology; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics / Q000502:physiology; D051057:Proto-Oncogene Proteins c-akt / Q000502:physiology; D016283:Proto-Oncogene Proteins p21(ras); D058570:TOR Serine-Threonine Kinases / Q000502:physiology; D018631:ras Proteins / Q000235:genetics / Q000502:physiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab; D066246:ErbB Receptors; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D011518:Proto-Oncogene Proteins; D048493:Proto-Oncogene Proteins B-raf; D051057:Proto-Oncogene Proteins c-akt; D016283:Proto-Oncogene Proteins p21(ras); D058570:TOR Serine-Threonine Kinases; D018631:ras Proteins; C117307:KRAS protein, human; C546842:MTOR protein, human; C482119:BRAF protein, human; C494929:PTEN protein, human
keywords: EGFR; RAS; cetxuximab; colorectal carcinoma; cost–effectiveness; pharmacogenomics; predictive; resistance